Compare GoPro Inc (GPRO) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GoPro Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? GoPro Inc trades at $1.1 (market cap $243.50M), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 20× GoPro Inc's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, GoPro Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold GoPro Inc for 45 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| GPRO | TVTX | |
|---|---|---|
Market Cap | $243.50M | $4.88B |
Volume | 7,074,005 | 1,668,577 |
Sector | Technology | Health |
52-Week High | $2.31 | $67.52 |
52-Week Low | $0.58 | $26.79 |
Typical Hold Time | 45 Days | 0 Days |
Enterprise Value | $302.28M | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GoPro trades at $1.16, down 2.52% today, as the stock consolidates after a volatile surge driven by merger news and influencer investment. The company faces fundamental challenges with negative profit margins and cash flow, though valuation ratios appear attractive with P/E of 4.56 and P/S of 0.34. Recent developments include a $285 million merger agreement with Starman Optical and YouTube creator Markiplier taking an 8.5% stake, driving significant price volatility.
The merger with Starman Optical offers strategic repositioning into AI data centers and defense markets, but shareholder lawsuits question the $1.14 per share valuation. While technical indicators show bullish momentum, fundamental weaknesses and competitive pressures from smartphones create significant investment risk. Analyst consensus remains cautious with only 21% buy ratings.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About GoPro Inc
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts, drones and appliances. The company outsources a part of manufacturing to third parties in China. The company sells products across the world through its direct sales channel, which generates over half of total revenue, and indirectly through its distribution channel. The company has presence, including in the Americas, Europe, Middle East, Africa, and Asia-Pacific, with the Americas contributing over half of total revenue.
Read more on GPRO →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
